Chang Y, Jeong S, Jang J
Front Med (Lausanne). 2022; 8:770124.
PMID: 35096867
PMC: 8795508.
DOI: 10.3389/fmed.2021.770124.
Onorato L, Pisaturo M, Camaioni C, Grimaldi P, Codella A, Calo F
J Clin Med. 2021; 10(21).
PMID: 34768721
PMC: 8584565.
DOI: 10.3390/jcm10215201.
Galimberti F, McBride J, Cronin M, Li Y, Fox J, Abrouk M
Clin Dermatol. 2020; 38(6):775-780.
PMID: 32419721
PMC: 7224642.
DOI: 10.1016/j.clindermatol.2020.05.003.
Moretto F, Catherine F, Esteve C, Blot M, Piroth L
J Clin Med. 2020; 9(1).
PMID: 31940817
PMC: 7019847.
DOI: 10.3390/jcm9010202.
Pattullo V
Clin Mol Hepatol. 2016; 22(2):219-37.
PMID: 27291888
PMC: 4946398.
DOI: 10.3350/cmh.2016.0024.
Prevention and management of hepatitis B virus reactivation in cancer patients.
Cheung K, Seto W, Lai C, Yuen M
Hepatol Int. 2016; 10(3):407-14.
PMID: 26739135
DOI: 10.1007/s12072-015-9692-3.
Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention.
Kato M, Atsumi T
Rheumatol Int. 2015; 36(5):635-41.
PMID: 26573663
DOI: 10.1007/s00296-015-3395-x.
Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations.
Mori S, Fujiyama S
World J Gastroenterol. 2015; 21(36):10274-89.
PMID: 26420955
PMC: 4579875.
DOI: 10.3748/wjg.v21.i36.10274.
Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure.
Pattullo V
World J Hepatol. 2015; 7(7):954-67.
PMID: 25954478
PMC: 4419099.
DOI: 10.4254/wjh.v7.i7.954.
Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients.
Laohapand C, Arromdee E, Tanwandee T
Hepatol Int. 2015; 9(2):202-8.
PMID: 25788188
DOI: 10.1007/s12072-014-9597-6.
Treatment of rheumatic diseases and hepatitis B virus coinfection.
Felis-Giemza A, Olesinska M, Swierkocka K, Wiesik-Szewczyk E, Haladyj E
Rheumatol Int. 2015; 35(3):385-92.
PMID: 25549599
PMC: 4335127.
DOI: 10.1007/s00296-014-3195-8.
Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs.
Tan J, Zhou J, Zhao P, Wei J
Clin Rheumatol. 2012; 31(8):1169-75.
PMID: 22544263
DOI: 10.1007/s10067-012-1988-2.
Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts.
Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H
J Gastroenterol. 2011; 46(4):556-64.
PMID: 21246383
DOI: 10.1007/s00535-010-0367-5.
[Infectious complications of biologic therapy in patients with rheumatoid arthritis].
Meyer-Olson D, Hoeper K, Schmidt R
Z Rheumatol. 2010; 69(10):879-88.
PMID: 21128049
DOI: 10.1007/s00393-010-0677-2.
Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in....
Visser K, Katchamart W, Loza E, Martinez-Lopez J, Salliot C, Trudeau J
Ann Rheum Dis. 2008; 68(7):1086-93.
PMID: 19033291
PMC: 2689523.
DOI: 10.1136/ard.2008.094474.
Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies.
Calabrese L, Zein N, Vassilopoulos D
Ann Rheum Dis. 2006; 65(8):983-9.
PMID: 16627542
PMC: 1798254.
DOI: 10.1136/ard.2005.043257.
